Patents by Inventor Mili MANDAL

Mili MANDAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CANCER WITH NK CELLS AND A CD38-TARGETED ANTIBODY
    Publication number: 20240115704
    Abstract: Provided herein are, among other things, methods for treating a patient suffering from a CD38+ cancer.
    Type: Application
    Filed: April 6, 2022
    Publication date: April 11, 2024
    Inventors: Peter FLYNN, Jason B. LITTEN, Thomas James FARRELL, John Kin Chuan LIM, Mili MANDAL, Srinivas Sai SOMANCHI, Yusun KIM, Sungyoo CHO, Yu Kyeong HWANG
  • EXPANDED AND STIMULATED NATURAL KILLER CELLS
    Publication number: 20240060046
    Abstract: Provided here, amongst other things, are populations of expanded and stimulated natural killer cells, pharmaceutical compositions comprising populations of expanded and stimulated natural killer cells, and methods of expanding and stimulating natural killer cells
    Type: Application
    Filed: December 16, 2021
    Publication date: February 22, 2024
    Inventors: Seungryel Han, Bokyung Min, Sungyoo Cho, Yu Kyeong Hwang, Jung Hyun Her, Yusun Kim, Eunji Kim, Hyojin Kim, Bitna Yang, Peter Flynn, Jason B. Litten, Thomas James Farrell, John Kin Chuan Lim, Mili Mandal
  • TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY
    Publication number: 20240000840
    Abstract: Provided herein are, among other things, methods for treating a patient suffering from a CD20+ cancer
    Type: Application
    Filed: December 16, 2021
    Publication date: January 4, 2024
    Inventors: Yu Kyeong Hwang, Jung Hyun Her, Yusun Kim, Eunji Kim, Hyojin Kim, Bitna Yang, Bokyung Min, Peter Flynn, Jason B. Litten, Thomas James Farrell, John Kin Chuan Lim, Mili Mandal
  • Anti-ICOS and anti-PD-1 antibody combination therapy
    Patent number: 11649289
    Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 16, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Sabyasachi Bhattacharya, Paul M. Bojczuk, Heather L. Jackson, Mili Mandal, Hong Shi, Sapna Yadavilli, Niranjan Yanamandra
  • ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS
    Publication number: 20230016034
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 19, 2023
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Mili MANDAL, Chia-Wei CHANG
  • ANTI-ICOS AND ANTI-PD-1 ANTIBODY COMBINATION THERAPY
    Publication number: 20190256599
    Abstract: The present invention provides methods for increasing expression of ICOS on an effector T cell comprising contacting said effector T cell with an anti-PD-1 antibody. The present invention also provides methods for decreasing expression of ICOS on a regulatory T cell comprising contacting said regulatory T cell with an anti-PD-1 antibody. The present invention provides methods for increasing sensitivity to an agent directed to ICOS in a human comprising administering to the human an anti-PD1 antibody. The present invention also provides methods of treating cancer in a human in need thereof comprising administering an anti-PD-1 antibody and an anti-ICOS antibody to said human, wherein the anti-PD-1 antibody increases T cell sensitivity to the ICOS antibody.
    Type: Application
    Filed: August 3, 2017
    Publication date: August 22, 2019
    Inventors: Sabyasachi BHATTACHARYA, Paul M. BOJCZUK, Heather L. JACKSON, Mili MANDAL, Hong SHI, Sapna YADAVILLI, Niranjan YANAMANDRA